Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection
AssigneeInventera Inc.
InventorTae-Hyun SHIN
Life of this patent
Estimating the term…
Loading patent…
AssigneeInventera Inc.
InventorTae-Hyun SHIN
Estimating the term…
Nanostructures that, after in vivo administration, are excreted in the urine via the kidneys without being phagocytosed by macrophages and/or metabolized, and their use as pharmaceutical compositions are disclosed. A nanostructure for in vivo administration contains (i) a spherical core formed by crosslinking one to three dextran molecules with an average molecular weight of 10,000 Da or less using a crosslinker and (ii) a discontinuous shell with divalent or trivalent iron ions coordinationally bonded to crosslinker-derived hydrophilic groups on the surface of the spherical core; and has (iii) a mass ratio of dextran to iron ranging from 100:2 to 100:10, and a charge ranging from −20 mV to 0 mV.
A nanostructure for in vivo administration that, after in vivo administration, is excreted in the urine via the kidneys without being phagocytosed by macrophages and/or metabolized, comprising
Dependencies are inferred from the claim text.